Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed aggressive non-Hodgkin lymphoma, including any of the following subtypes: * Follicular large cell lymphoma * Diffuse large cell lymphoma * Peripheral T-cell lymphoma * Transformed lymphoma * Lymphoblastic lymphoma * Burkitt or Burkitt-like lymphoma * Refractory or relapsed disease meeting the following criteria: * Patients who either did not respond to prior therapy or whose best response was partial response after ≥ 4 courses of chemotherapy * Histologic confirmation of relapsed or refractory disease is desirable but not mandatory and will be left to the discretion of the investigator * Must have evaluable or measurable disease * Patients who are candidates for stem cell or bone marrow transplantation allowed * No CNS involvement by lymphoma PATIENT CHARACTERISTICS: * ECOG performance status 0-3 * Absolute neutrophil count ≥ 1,000/mm³ (unless due to marrow infiltration by lymphoma) * Platelet count ≥ 100,000/mm³ (unless thrombocytopenia is due to marrow infiltration by lymphoma) * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless liver is involved with lymphoma, hemolysis, or Gilbert syndrome) * Serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥ 30 ml/min (unless creatinine elevation is due to lymphoma) * ALT ≤ 2 times ULN (≤ 5 times ULN if liver metastasis is involved with lymphoma) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effect…